Objective: There have been recent advances in the understanding of the etiology of idiopathic central precocious puberty (iCPP) including new genetic associations. The aim of this clinical study was to determine the frequency of MKRN3 mutation in cases of familial iCPP.

Methods: Potential sequence variations in the maternally imprinted MKRN3 gene were evaluated in 19 participants from 10 families using next-generation sequencing analysis.

Results: MKRN3 variation was found in only one of the 19 (5.3%) subjects. The male patient, who had a medical history of precocious puberty, had a heterozygous mutation, NM_005664.3:c.630_650delins GCTGGGC (p.P21 1Lfs*16). The father of this patient also had a history of precocious puberty and had the same mutation. p.P21 1Lfs*16 is a novel variant and it was identified as probably pathogenic by in silico analysis, consistent with the clinical findings.

Conclusion: Given that MKRN3 mutation was detected in only one patient, with a paternal history of precocious puberty, this reinforces the importance of accurate family history taking. The detected incidence of MKRN3 variants in our case series was much lower than reported elsewhere which suggests a need for further studies in Turkish iCPP patients.

Keywords: MKRN3 mutation, familial central precocious puberty, genetic analysis

Introduction

Central precocious puberty (CPP) is defined as the development of secondary sex characteristics before eight years of age in girls and nine years of age in boys, due to early activation of the hypothalamic-pituitary-gonadal (HPG) axis (1,2). Owing to recent advances in genetics, the underlying etiology has been revealed in some cases of idiopathic CPP (iCPP). Gain-of-function mutations in the KISS1 and KISSR1 genes and loss-of-function mutations in the makorin ring finger protein 3 (MKRN3) gene were shown to result in CPP (3,4,5).

The MKRN3 gene product exerts an inhibitory effect on gonadotropin releasing hormone (GnRH) neurons. It has been proposed that the HPG axis is reactivated by loss-of-
function mutations in the *MKRN3* gene (6). It was reported that the frequency of *MKRN3* was higher in cases with familial iCPP compared with sporadic cases (7,8). However, the frequency can vary according to ethnicity (9). The aim of this clinical study was to determine the frequency of MKRN3 mutation in a group of Turkish families with familial iCPP.

**Methods**

The study included siblings diagnosed with iCPP and iCPP cases with a positive family history who presented to the Endocrinology Outpatient Clinic of Dr. Sami Ulus Obstetrics and Gynaecology, Children’s Health and Disease Training and Research Hospital. All parents gave written informed consent before participation. The study was approved by the Ethics Committee of the Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey (46/2015). All children included in the study had at least one first or second degree relative with documented iCPP.

The Tanner and Marshall (10,11) criteria were used for puberty staging. Girls who had at least Tanner stage 2 breast development and stage 2 pubarche before eight years of age were assessed as cases of early puberty. Boys who had at least Tanner stage 2 testicular volume (>4 mL) or stage 2 pubarche before nine years of age were assessed as cases of early puberty.

In the girls luteinising hormone (LH), follicle-stimulating hormone (FSH) and 17β-estradiol (E2) were measured in a morning blood sample. A basal serum LH level ≥0.83 mIU/mL, with puberty precocious findings described above, was accepted as activation of the HPG axis (12). Cases with a basal LH level <0.83 mIU/mL underwent the standard stimulation test of 100 µg GnRH (Ferring Pharmaceuticals, North America) by intravenous injection between 8:00 and 8:30 am to assess early puberty. Blood samples were taken at 0, 30, 60, 90, and 120 min to measure serum LH and FSH levels. Peak LH ≥3.3 mIU/mL was accepted as the diagnostic criterion for activation of the HPG axis in girls (13). In boys, LH, FSH and testosterone were measured also in a morning blood sample. A basal serum LH level ≥0.83 mIU/mL, with puberty precocious findings described above, was accepted as activation of the HPG axis in boys (12). Cases with a basal LH level <0.3 mIU/mL underwent the standard stimulation test described above. Peak LH ≥4.1 mIU/mL was accepted as the diagnostic criterion for activation of the HPG axis (13).

Congenital adrenal hyperplasia was excluded by 17-hydroxyprogesterone (17-OHP) <1.5 ng/mL in early morning samples and/or peak 17-OHP <10 ng/mL following an ACTH stimulation test. Cranial magnetic resonance imaging (MRI) was performed to exclude any organic lesion in all cases diagnosed with CPP.

Standing height was measured to the nearest 0.1 cm with a Harpenden fixed stadiometer (Seritex, North America). Body weight was measured on a balance scale (SECA, North America) to the nearest 0.1 kg. Height and weight standard deviation score (SDS) were calculated by comparison with Turkish national reference data (www.ceddcozum.com) (14). Adult height prediction was calculated by dividing the height by the decimal fraction, using the table for predicting adult stature as described by Greulich and Pyle (15).

LH, FSH, and E2 levels were measured with an immunochemiluminometric assay using an Advia Centaur immunoanalyzer (Bayer Diagnostics, Tarrytown, NY, USA). Bone age (BA) was assessed according to the Greulich and Pyle (15) Atlas method.

**Genetic Analysis**

Genomic DNA was isolated from ethylenediamine tetraacetic acid blood sample by Magnesia DNA isolation Kit (Anatolia Geneworks, Istanbul, Turkey). Sequencing study was done by NGS technology and it was performed using the MiSeq next generation sequencing platform (llumina Inc., San Diego, CA, USA). All coding exons of *MKRN3* and flanking regions were amplified using polymerase chain reaction (PCR) primers, designed with PRIMER-Primer Designer v.2.0 software (Scientific and Educational Software program). Amplicon libraries were prepared with the NexteraXT kit (llumina Inc.). Sequences were aligned to the hg19 genome with MiSeq Reporter software (llumina Inc.). Detection of variants was performed with IGV 2.5 (Board Institute) software. In silico analysis, database search and literature evaluations were done by Varsome, Polyphen2, HGMD-Public, PubMed, Google search, Clinvar, EXAC and 1,000 Genome studies.

**Statistical Analysis**

The data obtained were evaluated using the SPSS 16.0 software programme (SPSS Inc., Chicago, IL, USA).

**Results**

The study included 19 patients with CPP from 10 families. In the familial CPP group, there were 17 girls and two boys (one boy with a paternal history of precocious puberty) from 10 families. Clinical, anthropometric and biochemical data of the included patients and their parents are displayed in Tables 1 and 2. Among the 17 girls with familial iCPP, mean age at the onset of secondary sex characteristics
| Family/patient no. | Current age, years | Puberty in parents | Sex | First clinical sign | Onset of puberty, years | Age at GnRH stimulation test, years | Tanner stage (T/P) | Height (cm)/height SD | Weight (kg)/weight SD | Bone age, years | Growth velocity (cm) year/treatment | LH, mIU/mL basal/stimulated | FSH, mIU/mL basal/stimulated |
|-------------------|-------------------|-------------------|-----|---------------------|------------------------|----------------------------------|------------------|----------------------|---------------------|----------------|-----------------------------|-----------------------------|-----------------------------|
| 1.1               | 10.3              | M: menarche 11 years | Female | T                  | 7.4                     | 7.8                              | 3/2              | 130/0.8               | 29/0.8              | 10            | 7/+                         | <0.07/3.3                   | 2.95/18                     |
| 1.1               | 6.5               | F: 13 years       | Female | T                  | 2                       | 3.3                              | 2/1              | 94.6/-0.6            | 13/0.9              | 5.5           | -/+                        | 0.32/6.2                     | 3.97/26.3                   |
| 2.1               | 11.3              | M: menarche 12.5 years | Female | P                  | 7                       | 7.7                              | 2/2              | 137.1/2.3            | 31/1.3              | 8.9           | 7/+                         | <0.07/8.2                    | <3/6.9                      |
| 2.2               | 14.5              | F: onset at 14 years | Female | P                  | 5.9                     | 6                                | 2/2              | 122.1/1.4            | 23.9/0.9            | 7.9           | -/+                         | <0.07/5.7                    | 3.6/18.3                    |
| 3.1               | 12.3              | M: menarche 11.5 years | Female | P                  | 4.8                     | 5                                | 2/1              | 106.6/-0.6           | 16/-1.1             | 5             | -/+                         | <0.1/5.3                     | 1.48/24.5                   |
| 3.2               | 16.3              | F: unknown        | Female | T                  | 5.5                     | 8.3                              | 3/2              | 126.4/-0.3           | 26.8/0.1            | 11            | 5.4/+                      | <0.5/5.25                    | 2.6/22.3                    |
| 4.1               | 12.1              | M: menarche 12 years | Male  | P                  | 8.9                     | 9.9                              | 2*/3             | 142.4/1              | 35.3/0.6            | 11.6          | 6.5/+                      | 0.87/18.3                    | <3/5.54                     |
| 4.2               | 14.2              | F: onset at 14 years | Female | T                  | 7.9                     | -                                | 3/2              | 136.4/1.3            | 36.7/1.6            | 10            | -/+                         | 1.11/-                      | 6.83/-                      |
| 5.1               | 10.7              | M: menarche 13.5 years | Female | T                  | 6.3                     | 7.1                              | 3/1              | 123.1/0.2            | 24.5/0.3            | 8.9           | 6.7/+                      | <0.07/4.67                   | <3/28.4                     |
| 5.2               | 13.1              | F: unknown        | Female | T                  | 7.9                     | 9                                | 3/1              | 143/1.9              | 45.4/2.3            | 11            | -/+                         | 0.15/11                     | 1.22/7.8                    |
| 6.1               | 10.9              | M: menarche 9.5 years | Female | T                  | 5.6                     | 6.8                              | 2/2              | 125.2/1              | 25.6/0.8            | 10            | -/+                         | <0.07/23.1                   | <3/13.3                     |
| 6.2               | 8.6               | F: onset at 13 years | Female | T                  | 6                       | 6.1                              | 2/2              | 122/1.4              | 27.8/1.8            | 8.9           | -/+                         | <0.07/4.68                   | 0.44/9.8                    |
| 7.1               | 12.3              | M: menarche 12 years | Female | P                  | 7                       | 7.3                              | 2/2              | 125.9/0.6            | 23.8/0.0            | 8.9           | -/+                         | 0.35/9.1                    | 7.93/41                     |
| 7.2               | 16                | F: unknown        | Female | P                  | 7.5                     | 7.5                              | 2/2              | 129/1                | 26/0.4              | 8.9           | -/+                         | 0.1/6.2                     | 3.7/19.4                    |
| 8.1               | 11.5              | M: menarche 12 years | Female | T                  | 7.5                     | 7.6                              | 2/2              | 117.6/-1.3           | 24/3.0              | 7.9           | -/+                         | <0.07/5.87                   | 5.56/16.6                   |
| 8.2               | 14.9              | F: unknown        | Female | T                  | 7                       | 7.1                              | 2/2              | 121.5/-0.0           | 22/0.7              | 7             | -/+                         | 0.14/6.56                   | 1.3/9.4                     |
| 9.1               | 12                | M: menarche 12 years | Female | T                  | 8                       | 9.1                              | 3/4              | 129.9/-0.5           | 25.3/-0.8           | 11            | 5/+                         | 0.14/5.69                   | 1.73/17.6                   |
| 9.2               | 10.5              | F: onset at 12 years | Female | T                  | 7                       | 7.4                              | 2/1              | 115.4/-1.5           | 21.6/-0.7           | 8.9           | -/+                         | 0.16/6.5                    | 1.79/19.8                   |
| 10.1*/&            | 13.2              | M: menarche 13.5 years | Male  | Acne, beard        | 9                       | -                                | 4*/*4            | 156.5/1.27           | 44/0.3              | 14            | Near final/-                | 5.41/-                      | 13.7/-                      |

M: Mother, F: Father, T: Thearche, P: Adrenarche, *: The father had a history of precocious puberty, **: Tanner stage for male, &: MKRN3-mutation-positive patient, SD: standard deviation, LH: luteinising hormone, FSH: follicle-stimulating hormone, GnRH: gonadotropin releasing hormone
was 6.5 ± 1.5 years, and mean age at treatment onset was 7.2 ± 1.4 years. In this group, the mean BA was 8.7 ± 2.0 years, and the BA:CA ratio was 1.2 ± 0.1. The 17-OHP level was normal in all cases with pubarche. Therefore, none of the patients proceeded to an ACTH stimulation test. Cranial MRI was normal in all cases.

Among the whole group, a novel heterozygous mutation, MKRN3:NM_005664.3:c.630_650delinsGCTGGGC (p.P211Lfs*16), was detected in only one boy with a paternal history of precocious puberty (Figure 1). A flow chart of patient and family recruitment into the study is shown in Figure 2. MKRN3 gene analysis was performed only in this patient’s father. We did not have the opportunity to study the genotype in his remaining family members. The patient with MKRN3 mutation presented with facial hair growth at 11 years and 7 months of age. Facial hair growth had appeared 1.5 years earlier. Family history revealed that facial hair growth had appeared at the same age in his father. The patient’s brother is unaffected and was found to be pre-pubertal in the examination performed at 10 years of age. The patient’s physical examination yielded the following findings: height, 156.5 cm (+1.27 standard deviation (SD)); body weight, 44.6 kg (+0.3 SD); 15 mL testicular volume bilaterally; stage 5

Table 2. Anthropometric characteristics of patients’ parents, target and predicted height of patients

| Family/patient no. | Current age, years | Sex | Onset of puberty, years | Mother’s height (cm)/SD | Father’s height (cm)/SD | Target height cm/SD | Predicted height (cm)/SD | Difference in height SD-target height SD | Difference in target height SD-predicted height SD |
|--------------------|--------------------|-----|-------------------------|-------------------------|-------------------------|-----------------------|-------------------------|---------------------------------|---------------------------------|
| 1.1                | 10.3               | Female | 7.4                     | 15I/-1.86               | 168/-1.17               | 153/-1.55            | 143.5/-3               | 2.4                             | 1.45                           |
| 1.1                | 6.5                | Female | 2                       | 15I/-1.86               | 168/-1.17               | 153/-1.55            | -                       | 1                               | -                              |
| 2.1                | 11.3               | Female | 7                       | 164.9/-0.27            | 171/-0.76               | 161.5/-0.26          | 167/-0.6               | 2.6                             | 0.86                           |
| 2.2                | 14.5               | Female | 5.9                     | 164.9/-0.27            | 171/-0.76               | 161.5/-0.26          | 156.1/-1.1             | 1.7                             | 0.84                           |
| 3.1                | 12.3               | Female | 4.8                     | 149.8/-2.04            | 164/-1.7                | 150.4/-1.95          | -                       | 1.4                             | -                              |
| 3.2                | 16.3               | Female | 5.5                     | 149.8/-2.04            | 164/-1.7                | 150.4/-1.95          | 139.5/-3.6             | 1.7                             | 1.65                           |
| 4.1                | 12.1               | Male   | 8.9                     | 149/-2.16              | 167/-1.3                | 164.5/-1.65          | 174/-0.4               | 2.65                            | -1.25                          |
| 4.2                | 14.2               | Female | 7.9                     | 149/-2.16              | 167/-1.3                | 151.5/-1.78          | 158.2/-0.8             | 3.1                             | -0.98                          |
| 5.1                | 10.7               | Female | 6.3                     | 153.8/-1.43            | 173/-0.49               | 156.9/-0.96          | 150/-2                 | 1.2                             | 1.04                           |
| 5.2                | 13.1               | Female | 7.9                     | 153.8/-1.43            | 173/-0.49               | 156.9/-0.96          | 158/-0.8               | 2.9                             | -0.16                          |
| 6.1                | 10.9               | Female | 5.6                     | 159/-0.64              | 167/-1.31               | 156.5/-1.02          | 145.2/-2.8             | 2                               | 1.78                           |
| 6.2                | 8.6                | Female | 6                       | 159/-0.64              | 167/-1.31               | 156.5/-1.02          | 148.5/-2.2             | 2.4                             | 1.18                           |
| 7.1                | 12.3               | Female | 7                       | 167/0.59               | 172/-0.6               | 163/0                 | 153.5/-1.5            | 0.6                             | -0.6                           |
| 7.2                | 16                 | Female | 7.5                     | 167/0.59               | 172/-0.6               | 163/0                 | 157.1/-0.9            | 1                               | -1                             |
| 8.1                | 11.5               | Female | 7.5                     | 152/-1.1.7             | 169/-1                 | 154/-1.4             | 150.3/-2              | 0.1                             | 1.5                            |
| 8.2                | 14.9               | Female | 7                       | 152/-1.1.7             | 169/-1                 | 154/-1.4             | 160.5/-0.4            | 1.4                             | -2.8                           |
| 9.1                | 12                 | Female | 8                       | 152/-1.7              | 175/-0.2               | 157/-0.9             | 143.3/-3              | 0.4                             | -1.3                           |
| 9.2                | 10.5               | Female | 7                       | 152/-1.7              | 175/-0.2               | 157/-0.9             | 140.5/-3.5            | -0.6                            | -0.3                           |
| 10.1* & 13.2       | Male               | 9     | 167/0.6                 | 159/-2.4              | 169.5/-1              | 168.8/-1.1           | 2.3                             | 2.3                             | -3.3                           |

*: The father had a history of precocious puberty, &: MKRN3-mutation-positive patient, SD: standard deviation

Figure 1. Mutation image of MKRN3 gene of the patient with IGV2.3 software [NM_005664.3:c.630_650delins GCTGGGC (p.P211Lfs*16)] and Varsome software image
pubarche; and axillary hair growth. The heights of mother
and father were 167 (+0.6 SDS) and 159 cm (-2.4 SDS),
respectively. The patient’s target height and predicted
height were estimated to be 169.5 cm (-1 SDS) and 168.8
cm (-1.1 SDS), respectively. Routine biochemistry tests
and complete blood count were normal. The hormone
test results were as follows: LH, 5.4 mIU/mL; FSH, 13.7
mIU/mL; total testosterone: 393.3 ng/dL; 17OHP: 0.6 ng/
ml; and dehydroepiandrosterone sulphate, 60.4 mcg/dL.
BA 14 years. The same mutation was also detected in his
father.

The physical examination of the other boy with no
mutation showed height 142.4 cm (1 SDS), weight 35.3
kg (0.6 SDS); 6 mL testicular volume bilaterally; stage 3
pubarche; and axillary hair growth. The heights of mother
and father were 149 cm (-2.16 SDS) and 167 cm (-1.3 SDS),
respectively. The patient’s target height and predicted
height were estimated to be 164.5 cm (-1.65 SDS) and 174
cm (-0.4 SDS), respectively. The patient was followed-up
without treatment due to slowly progressive puberty.

This mutation is a frame shift variant and causing production
of a truncated protein with 226 amino acids while the wild
type protein consists of 507 amino acids. Mutation taster
predicts this variant as a disease-causing mutation, probably
due to loss of function.

Discussion

MRKN3, which encodes the MRKN3, is an intronless gene
located on chromosome 15q11.2 in the Prader–Willi
syndrome critical region (16). The imprinted MRKN3 gene
is expressed only in the paternal allele, and it affects both
sexes equally, in contrast to female preponderance in iCPP
cases (16). The presence of a history of paternal precocious
puberty, shorter final height and detection of MRKN3
gene mutation confirm paternal inheritance. The MRKN3
protein, a product of this gene, includes two copies of a C3H
motif in the N-terminal, a novel Cys–His configuration, a
C3HC4 RING zinc finger, and a final C3H motif (6). A novel
frameshift mutation (between C3H motifs in the N-terminal)
in the imprinted MRKN3 gene was identified in one male
case and his affected father. In silico analysis suggested that
this variant would be pathogenic. Scrutiny of human genetic
variant databases revealed that this variant had not been
previously reported.

In their study, Abreu et al (5) found a loss-of-function
mutation in the MRKN3 gene associated with familial
iCPP. This work led to an investigation of the mechanism
underlying familial iCPP, which has been important
not only for understanding iCPP but also for a better
understanding of the timing of normal puberty in
humans. Since 2013, MRKN3 mutation has been the
most frequently identified genetic cause of iCPP. The
authors screened 40 individuals with familial iCPP
from 15 families for MRKN3 mutations, and reported
identifying MRKN3 mutation in 15 individuals from five
families (37.5%) (5). In another study, MRKN3 mutation
was detected in 13 of 28 cases (46%) with familial iCPP,
and in only one of 18 cases with sporadic iCPP (7). In
a study of 20 boys with iCPP from 17 families, Bessa
et al (17) detected MRKN3 mutation in eight boys from
five families. The authors emphasised the importance of
investigating boys with MRKN3 mutation and a history
of paternal precocious puberty. In a recent study from
Turkey, Simsek et al (18) reported that two heterozygous
frameshift mutations were identified in the MRKN3 gene
in two probands with familial iCPP and in seven patients
with iCPP, as well as 11 unaffected family members. We
investigated 19 individuals from 10 families with iCPP
and found one novel frameshift (5.3%) mutation. Simsek
et al (18) reported that due to the imprinted pattern of
inheritance, the phenotype skipped one generation in one
family because the proband’s father and paternal uncle
had inherited the mutated allele from their mothers. They
also showed that in another family, because the proband’s
father and affected paternal cousin’s father had inherited
the mutated allele from the paternal grandfather,
the phenotype was present in the second and third
generations. A paternal aunt in the latter family also had
iCPP, but her children were asymptomatic carriers of the
same mutation. As those authors suggested, and as the
history of our patient with MRKN3 mutation highlights,
an accurate family history is extremely important, as it
can reveal the paternal inheritance of familial iCPP due
to a mutation in MRKN3. Physicians should consider this

Figure 2. Flow chart of the study recruitment

CPP: central precocious puberty, iCPP: idiopathic central precocious puberty
type of inheritance in patients with iCPP thus allowing targeted MKRN3 genetic analysis, thereby providing an additional tool for the diagnosis of children with iCPP.

In boys, there may be delay in recognising indicators of precocious puberty compared with those (thelarche, menarche) in girls (5,8,9,19,20). The findings of precocious puberty were not recognised by the family in our MKRN3 mutation case, and he presented at the hospital at a late pubertal stage, when he began to shave his facial hair. In the literature, the mean age at onset of puberty was reported as 8.2 years in 13 boys with MKRN3 mutation (5,17,19). Given that age at onset of puberty is approximately six years of age in girls with MKRN3 mutation (5,16,20), pubertal onset appears to be more precocious in affected girls (around two years) than in affected boys (around 0.8 years). In addition, the time from the onset of pubertal symptoms to diagnosis is longer in boys (5,21). It has been reported that puberty can be successfully suppressed by GnRH agonist treatment in cases with MKRN3 mutation and that menarche and other pubertal indicators show a normal course following treatment (5,7,22).

Study Limitations
The small number of patients and the wide range of criteria which were used to diagnose CPP were the limitations of this study.

Conclusion
MKRN3 mutation was detected in only one (5.3%) of 19 individuals from 10 families with familial CPP. Given the fact that the MKRN3 mutation was detected in only one patient with a paternal history of precocious puberty in our study, the importance of an accurate family history, which can reveal the paternal inheritance of familial iCPP due to a mutation in MKRN3, must be emphasized. Physicians should consider this type of inheritance in patients with iCPP thus facilitating targeted genetic analysis and providing an additional tool for the diagnosis of children with iCPP.

Ethics
Ethics Committee Approval: The study was approved by the Ethics Committee of the Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey (46/2015), and was conducted according to the principles of the Declaration of Helsinki.

Informed Consent: Written consent was obtained from all subjects and their parents before the study.

Peer-review: Internal and external peer-reviewed.

Authorship Contributions
Surgical and Medical Practices: Erdal Kurnaz, Şenay Savaş-Erdeve, Semra Çetinkaya, Zehra Aycan, Concept: Erdal Kurnaz, Şenay Savaş-Erdeve, Semra Çetinkaya, Zehra Aycan, Design: Zehra Aycan, Şenay Savaş-Erdeve, Gülay Ceylaner, Data Collection or Processing: Zehra Aycan, Şenay Savaş-Erdeve, Semra Çetinkaya, Erdal Kurnaz, Melikşah Keskin, Nursel Muratoğlu Şahin, Elvan Bayramoğlu, Analysis or Interpretation: Erdal Kurnaz, Şenay Savaş-Erdeve, Gülay Ceylaner, Literature Search: Erdal Kurnaz, Şenay Savaş-Erdeve, Writing: Erdal Kurnaz, Şenay Savaş-Erdeve, Zehra Aycan.

Financial Disclosure: The authors declare that this study received no financial support.

References
1. Diamantopoulos S, Bao Y. Gynecomastia and premature thelarche: a guide for practitioners. Pediatr Rev 2007;28:57-68.
2. Ibanez L, Virdis R, Potau N, Zampolli M, Ghizzoni L, Albisu MA, Carrascosa A, Bernasconi S, Vicens-Calvet E. Natural history of premature pubarche: an auxological study. J Clin Endocrinol Metab 1992;74:254-257.
3. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, Seminara SB, Mendonca BB, Kaiser UB, Latorrico AC. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008;358:709-715.
4. Silveira LG, Noel SD, Silveira-Neto AP, Abreu AP, Brito VN, Santos MG, Bianco SD, Kuohung W, Xu S, Gryngarten M, Escobar ME, Arnhold IJ, Mendonca BB, Kaiser UB, Latorrico AC. Mutations of the KISS1 gene in disorders of puberty. J Clin Endocrinol Metab 2010;95:2276-2280. Epub 2010 Mar 17
5. Abreu AP, Dauber A, Macedo DB, Noel SD, Brito VN, Gill JC, Cukier P, Thompson IR, Navarro VM, Gagliardi PC, Rodrigues T, Kochi C, Longui CA, Beckers D, de Zegher F, Montenegro LR, Mendonca BB, Carroll RS, Hirschhorn JN, Latorrico AC. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med 2013;368:2467-2475. Epub 2013 Jun 5
6. Abreu AP, Macedo DB, Brito VN, Kaiser UB, Latorrico AC. A new pathway in the control of the initiation of puberty: the MKRN3 gene. J Mol Endocrinol 2015;54:131-139.
7. Simon D, Ba I, Mekhall N, Ecosse E, Fausen A, Zanaty D, Houang M, Jesuran Perelroizen M, de Filippo GP, Salerno M, Simonin G, Reynaud R, Carel JC, Léger J, de Roux N. Mutations in the maternally imprinted gene MKRN3 are common in familial central precocious puberty. Eur J Endocrinol 2016;174:1-8. Epub 2015 Oct 1
8. de Vries L, Gat-Yablonski G, Dror N, Singer A, Phillip M. A novel MKRN3 missense mutation causing familial precocious puberty. Hum Reprod 2014;29:2838-2843. Epub 2014 Oct 14
9. Lee HS, Jin HS, Shim YS, Jeong HR, Kwon E, Choi V, Kim MC, Chung IS, Jeong SY, Hwang JS. Low Frequency of MKRN3 Mutations in Central Precocious Puberty Among Korean Girls. Horm Metab Res 2016;48:118-122. Epub 2015 May 4
10. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
11. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23.
12. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics 2009;123:1059-1063.

13. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424-1429. Epub 2007 Feb 6

14. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol 2015;7:280-293.

15. Radiographic Atlas of Skeletal Development of the Hand and Wrist. Greulich WW, Pyle SI. California, Stanford University Press, 1959.

16. Jong MT, Gray TA, Ji Y, Glenn CC, Saitoh S, Driscoll DJ, Nichols RD. A novel imprinted gene, encoding a RING zinc-finger protein, and overlapping antisense transcript in the Prader-Willi syndrome critical region. Hum Mol Genet 1999;8:783-793.

17. Macedo DB, Abreu AP, Reis AC, Montenegro LR, Dauber A, Beneduzzi D, Cukier P, Silveira LF, Teles MG, Carroll RS, Junior GG, Filho GG, Gucev Z, Arnhold IJ, de Castro M, Moreira AC, Martinelli CE Jr, Hirschhorn JN, Mendonca BB, Brito VN, Antonini SR, Kaiser UB, Latronico AC. Central precocious puberty that appears to be sporadic caused by paternally inherited mutations in the imprinted gene makorin ring finger 3. J Clin Endocrinol Metab 2014;99:1097-1103. Epub 2014 Mar 14

18. Simsek E, Demiral M, Ceylaner S, Krel B. Two Frameshift Mutations in MKRN3 in Turkish Patients with Familial Central Precocious Puberty. Horm Res Paediatr 2017;87:405-411. Epub 2016 Nov 1

19. Settas N, Dacou-Voutetakis C, Karantza M, Kanaka-Gantenbein C, Chrousos GP, Voutetakis A. Central precocious puberty in a girl and early puberty in her brother caused by a novel mutation in the MKRN3 gene. J Clin Endocrinol Metab 2014;99:647-651. Epub 2014 Jan 17

20. Schreiner F, Gohlke B, Hamm M, Korsch E, Woelfle J. MKRN3 mutations in familial central precocious puberty. Horm Res Paediatr 2014;82:122-126. Epub 2014 Jul 5

21. Hagen CP, Sørensen K, Mieritz MG, Johannsen TH, Almstrup K, Juul A. Circulating MKRN3 levels decline prior to pubertal onset and through puberty: a longitudinal study of healthy girls. J Clin Endocrinol Metab 2015;100:1920-1926. Epub 2015 Feb 19